Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Targeting 'molecular bodyguards' weakens prostate cancer cells

Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

Females found to carry a higher genetic risk of depression

An international team of scientists has discovered about twice as many genetic 'flags'...

Widespread resistance to common antibiotics is increasing: WHO

Increasing resistance to essential antibiotics poses a growing threat to global health, with one...

Content from other channels on our network

Roma Foods celebrates over 70 years of Australian manufacturing

$300m production facility for frozen chips being built in Vic

Barry Callebaut and Planet A Foods partner to progress sustainable chocolate

Company fined $300K after worker injured in a chilled meat storage area

FSANZ's annual report defined by safety & scientific progress

Nominations open for 2026 HESTA Australian Nursing & Midwifery Awards

Report explores Australian perceptions of Medtech access

Vertical healing: redefining health care through high-rise hospital design

Using better network insight to boost productivity in Australian health care

Construction underway on new Redcliffe cancer care centre

Discovery improves silicon solar efficiency

Partnership to redefine thermal comfort index

Dashboard to support climate-aware business decisions

Australia's homes aren’t ready for the heat — here's how to fix them

Program assists power station workers to find new careers